110 related articles for article (PubMed ID: 8984321)
1. [Health care economics evaluation of inpatient treatment of venous thrombosis with unfractionated heparin versus subcutaneous low molecular weight heparin at home].
Osterkorn D; Schramm W; Szucs T
Med Klin (Munich); 1996 Sep; 91(9):607-9. PubMed ID: 8984321
[TBL] [Abstract][Full Text] [Related]
2. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. TASMAN Study Group.
van den Belt AG; Bossuyt PM; Prins MH; Gallus AS; Büller HR
Thromb Haemost; 1998 Feb; 79(2):259-63. PubMed ID: 9493572
[TBL] [Abstract][Full Text] [Related]
3. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective.
Hull RD; Raskob GE; Rosenbloom D; Pineo GF; Lerner RG; Gafni A; Trowbridge AA; Elliott CG; Green D; Feinglass J
Arch Intern Med; 1997 Feb; 157(3):289-94. PubMed ID: 9040295
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of ambulatory and inpatient treatment of acute deep venous thrombosis of the leg: subjective and economic aspects].
Frank D; Blättler W
Schweiz Med Wochenschr; 1998 Sep; 128(36):1328-33. PubMed ID: 9784675
[TBL] [Abstract][Full Text] [Related]
5. [Therapy of thromboses with low-molecular-weight heparins].
Haas S; Haas P
Wien Med Wochenschr; 1999; 149(2-4):39-45; discussion 45. PubMed ID: 10378321
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of hospital cost of six days of treatment of deep venous thrombosis. Comparison of subcutaneous nadroparin and intravenous heparin in 40 patients].
Lévesque H; Cailleux N; Vasse D; Legallicier B; Moore N; Borg JY; Hantute N; Thuillez C; Courtois H
Therapie; 1994; 49(2):101-5. PubMed ID: 7817331
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.
McGarry LJ; Thompson D; Weinstein MC; Goldhaber SZ
Am J Manag Care; 2004 Sep; 10(9):632-42. PubMed ID: 15515996
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
[TBL] [Abstract][Full Text] [Related]
9. Should low-molecular-weight heparins replace unfractionated heparin as the agent of choice for adults with deep venous thrombosis?
Brewer D
J Fam Pract; 1998 Sep; 47(3):185-92. PubMed ID: 9752370
[TBL] [Abstract][Full Text] [Related]
10. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin.
Smith BJ; Weekley JS; Pilotto L; Howe T; Beven R
Intern Med J; 2002; 32(1-2):29-34. PubMed ID: 11783670
[TBL] [Abstract][Full Text] [Related]
11. [Standard heparin versus low-molecular-weight heparin].
Lockner D
Wien Med Wochenschr; 1999; 149(2-4):37-8. PubMed ID: 10378320
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
Prandoni P; Carnovali M; Marchiori A;
Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
[TBL] [Abstract][Full Text] [Related]
13. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
Hull RD; Pineo GF; Stein P
Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
[TBL] [Abstract][Full Text] [Related]
15. [Unfractionated standard heparin versus low molecular weight heparins].
Schrader J; Haas S
Internist (Berl); 1993 Nov; 34(11):1053-7; discussion 1058. PubMed ID: 8282491
[No Abstract] [Full Text] [Related]
16. Low molecular weight heparin for the prevention and treatment of venous thromboembolism.
Raskob GE
Curr Opin Pulm Med; 1996 Jul; 2(4):305-10. PubMed ID: 9363157
[TBL] [Abstract][Full Text] [Related]
17. Unfractionated versus low-molecular-weight heparin for deep venous thrombosis.
Penner J
N Engl J Med; 1996 Aug; 335(9):671; author reply 671-2. PubMed ID: 8692247
[No Abstract] [Full Text] [Related]
18. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects.
Hull RD; Pineo GF; Raskob GE
Haemostasis; 1998; 28 Suppl 3():8-16. PubMed ID: 10069757
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous unfractionated heparin for the treatment of venous thromboembolism.
Kearon C
Curr Opin Pulm Med; 2007 Sep; 13(5):398-402. PubMed ID: 17940484
[TBL] [Abstract][Full Text] [Related]
20. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
